Biovision 2013: Biovision Investor Conference, 330 million euro cumulative fund raising by the 35 selected companies

22 March 2013

The Biovision Investor Conference selection committee, held on 1st March 2013, selected 35 companies to showcase during the Biovision Investor Conference 2013 to be held 25th and 26th March 2013, in Lyon in conjunction with the world life sciences forum.

The prestigious selection committee, representing nearly € 10 billion under management, is chaired by Roman Fleck, Index Ventures and is coordinated by Jean-Marc Soustre, Humaneye Invest. In total, approximately 280 company evaluations were performed. The selection reflects a great diversity (11 countries), all activity sectors included: biopharma, medtech and healthcare services.

The total amount of funds sought by these 35 companies represents more than € 330 million, reflecting the dynamism of the life sciences sector in Europe. Applications included companies based in the United States of America and Australia and looking to relocate to Europe.

The Biovision Investor Conference 2013 brings together industry decision-makers with 3 key highlights:

  • the presentation of innovation strategies of world's leading industial groups,
  • pitches of young companies seeking for funding,
  • workshops around the first presentation of both the European Commission "Horizon 2020" programme and the European Investment Fund.

Biovision Investor Conference is co-organised by Lyonbiopôle and France Biotech, in partnership with EuropaBio.

Find out more

Biovision, the world life sciences forum, is organized since 1999 in Lyon by the Fondation pour l'Université de Lyon, an independent non-profit organization. Biovision brings together top decision-makers from the academic, private, policy-making and civil society sectors to translate innovative ideas into actionable solutions for the benefit of citizens.

Biovision 2013, the world life sciences forum, will be held from 24th to 26th March 2013 in Lyon, France.